ProCE Banner Activity

ExpressPoints: New Opportunities and Clinical Challenges Using Immunotherapies for TNBC

Slideset Download
Download this short summary slideset of key takeaways from a CCO live Webinar for an expert overview on incorporating immune checkpoint inhibitors and antibody–drug conjugates into optimal management of early-stage and advanced TNBC.

Released: December 16, 2020

Expiration: December 15, 2021

No longer available for credit.

Share

Faculty

Kevin Kalinsky

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Heather McArthur

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Rita Nanda

Rita Nanda, MD

Associate Professor of Medicine
Director, Breast Oncology
Section of Hematology/Oncology
Department of Medicine
The University of Chicago
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech, a member of the Roche Group

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Rita Nanda, MD

Associate Professor of Medicine
Director, Breast Oncology
Section of Hematology/Oncology
Department of Medicine
The University of Chicago
Chicago, Illinois